株式会社メトセラ

Site unreachable

Metcela is a clinical-stage biotech startup providing patients with an alternative treatment option for heart disease.

What it does

"Metcela is a clinical-stage biotech startup focused on maximizing the potential of cells, particularly in the treatment of heart failure. Their technology revolves around VCAM-1-positive Cardiac Fibroblast (VCF), which stimulates the growth and movement of myocardial cells, leading to the formation of robust heart tissue. This enables the development of regenerative medical products using the patient's own cells. With recent news of a former Bayer Pharmaceuticals leader joining as an external director, Metcela is strengthening its global presence and enhancing the development of its clinical pipeline. Recognized in various media outlets for their innovative approach in the field of cell therapy, Metcela's pioneering technology and global expansion strategy are poised to deliver promising results in the realm of regenerative medicine."

Next to it in Healthcare and bio · Cardiac regenerative medicine

  • Cell Factor Inc.Plug and Play

    Renewal medicine 3 elements +1 authentic society implementation -from postcolona, ​​from intractable diseases to pre -empty medical care. / 再生医療3要素 +1の本格社会実装 ~ポストコロナ、難病から先制医療まで~

  • iHeart JapanPlug and Play

    iHeart Japan is developing regenerative medicinal products for severe heart failure, using iPSC technologies.

  • マイキャン・テクノロジーズ株式会社Plug and Play

    MiCAN Technologies medical and nursing Care company.

  • 株式会社幹細胞&デバイス研究所Plug and Play

    Stem Cell & Device Laboratory is aiming to contribute to a healthy society with new cell application products.

  • 株式会社セルージョンPlug and Play

    Cellusion is a developer of corneal endothelial regenerative medicine intended to improve world visibility.

  • 株式会社ヘリオスPlug and Play

    Healios develops treatments for retinal diseases and age-related macular degeneration (AMD) using cell technology.

  • 株式会社マトリクソームPlug and Play

    Matricome develops regenerative medicines by disseminating laminin E8 fragment technology.

  • Rege NephroPlug and Play

    Rege Nephro is a biotech company that specialized in R&D, production and marketing of renal disease therapeutics.